The efficacy and safety were assessed with AIMS,BPRS and TESS at the end of week 1,2,4 and 6.

• 采用异常不自主运动量表(AIMS)和简明精神病评定量表(BPRS)及副反应量表(TESS)在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。